Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience.

Valeriani M, Marinelli L, Macrini S, Reverberi C, Aschelter AM, De Sanctis V, Marchetti P, Tronnolone L, Osti MF.

Radiat Oncol. 2019 Nov 14;14(1):205. doi: 10.1186/s13014-019-1414-x.

2.

Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.

Yamada Y, Matsubara N, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S.

BMC Res Notes. 2016 Oct 18;9(1):471.

3.

Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.

Giacinti S, Carlini P, Roberto M, Bassanelli M, Strigari L, Pavese F, Aschelter AM, Felici A, Valeriani M, Cognetti F, Marchetti P.

Anticancer Drugs. 2017 Jan;28(1):110-115.

PMID:
27763885
4.

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.

Conteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, Scarpi E, Castro E, Marin-Aguilera M, Lolli C, Schepisi G, Maugeri A, Wingate A, Farolfi A, Casadio V, Medina A, Puente J, Vidal MJM, Morales-Barrera R, Villa-Guzmán JC, Hernando S, Rodriguez-Vida A, González-Del-Alba A, Mellado B, Gonzalez-Billalabeitia E, Olmos D, Attard G, De Giorgi U.

Eur Urol. 2019 Mar;75(3):368-373. doi: 10.1016/j.eururo.2018.09.049. Epub 2018 Oct 26.

5.

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.

Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES.

Prostate. 2014 Sep;74(13):1278-85. doi: 10.1002/pros.22844. Epub 2014 Jul 22.

6.

AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.

Seitz AK, Thoene S, Bietenbeck A, Nawroth R, Tauber R, Thalgott M, Schmid S, Secci R, Retz M, Gschwend JE, Ruland J, Winter C, Heck MM.

Eur Urol. 2017 Nov;72(5):828-834. doi: 10.1016/j.eururo.2017.07.024. Epub 2017 Aug 14.

PMID:
28818355
7.

AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.

Okegawa T, Ninomiya N, Masuda K, Nakamura Y, Tambo M, Nutahara K.

Prostate. 2018 Jun;78(8):576-582. doi: 10.1002/pros.23501. Epub 2018 Mar 5.

PMID:
29508425
8.

Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials.

Wang Y, Zhang H, Shen W, He P, Zhou Z.

J Cancer Res Clin Oncol. 2018 Sep;144(9):1751-1768. doi: 10.1007/s00432-018-2664-y. Epub 2018 May 24. Review.

PMID:
29797220
9.

Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study.

Maughan BL, Luber B, Nadal R, Antonarakis ES.

Prostate. 2017 Jan;77(1):33-40. doi: 10.1002/pros.23246. Epub 2016 Aug 16.

PMID:
27527643
10.

Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.

Thomsen FB, Røder MA, Rathenborg P, Brasso K, Borre M, Iversen P.

Scand J Urol. 2014 Jun;48(3):268-75. doi: 10.3109/21681805.2013.860189. Epub 2013 Nov 21.

PMID:
24255983
11.

Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.

Pilon D, Queener M, Lefebvre P, Ellis LA.

J Med Econ. 2016 Aug;19(8):777-84. doi: 10.3111/13696998.2016.1173042. Epub 2016 Apr 20.

PMID:
27031255
12.

Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.

Nadal R, Tsai HL, Sinibaldi VJ, Paller CJ, Antonarakis ES, Denmeade SR, Carducci MA, Eisenberger MA.

Prostate. 2016 Apr;76(5):512-20. doi: 10.1002/pros.23141. Epub 2015 Dec 22.

PMID:
26689606
13.

Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.

Davies RS, Smith C, Lester JF.

Anticancer Res. 2016 Apr;36(4):1799-803.

PMID:
27069162
14.

Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.

Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman HT, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, Chi KN, Yu EY.

Prostate Cancer Prostatic Dis. 2015 Jun;18(2):122-7. doi: 10.1038/pcan.2014.53. Epub 2015 Jan 20.

15.

Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong.

Poon DMC, Wong KCW, Chan TW, Law K, Chan K, Lee EKC, Lee C, Chan M; Hong Kong Society of Uro-Oncology (HKSUO).

Clin Genitourin Cancer. 2018 Oct;16(5):402-412.e1. doi: 10.1016/j.clgc.2018.07.008. Epub 2018 Jul 21. Erratum in: Clin Genitourin Cancer. 2019 Jun;17(3):240.

16.

Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.

de Bono JS, Chowdhury S, Feyerabend S, Elliott T, Grande E, Melhem-Bertrandt A, Baron B, Hirmand M, Werbrouck P, Fizazi K.

Eur Urol. 2018 Jul;74(1):37-45. doi: 10.1016/j.eururo.2017.07.035. Epub 2017 Aug 23.

17.

Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program.

Papazoglou D, Wannesson L, Berthold D, Cathomas R, Gillessen S, Rothermundt C, Hasler L, Winterhalder R, Barth A, Mingrone W, Nussbaum CU, von Rohr L, von Burg P, Schmid M, Richner J, Baumann S, Kühne R, Stenner F, Rothschild SI.

Clin Genitourin Cancer. 2017 Jun;15(3):e315-e323. doi: 10.1016/j.clgc.2016.06.011. Epub 2016 Jun 23.

PMID:
27450512
18.

Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy.

Detti B, D'Angelillo RM, Ingrosso G, Olmetto E, Francolini G, Triggiani L, Bruni A, Borghesi S, Fondelli S, Carfagno T, Santini R, Santoni R, Trodella LE, Livi L.

Anticancer Res. 2017 Jul;37(7):3717-3722.

PMID:
28668865
19.

Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.

Emamekhoo H, Barata PC, Edwin NC, Woo KM, Grivas P, Garcia JA.

Clin Genitourin Cancer. 2018 Dec;16(6):429-436. doi: 10.1016/j.clgc.2018.08.002. Epub 2018 Aug 17.

PMID:
30236961
20.

The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.

Hung J, Taylor AR, Divine GW, Hafron JM, Hwang C.

Clin Genitourin Cancer. 2016 Oct;14(5):381-388. doi: 10.1016/j.clgc.2016.03.021. Epub 2016 Mar 24.

PMID:
27157640

Supplemental Content

Support Center